Andrew Ciupek, PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Novartis
    Date added:
    06/28/2024
    Date updated:
    06/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Seagen
    Date added:
    06/28/2024
    Date updated:
    06/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Gilead
    Date added:
    06/28/2024
    Date updated:
    06/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Regeneron
    Date added:
    06/28/2024
    Date updated:
    06/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Daiichi Sankyo
    Date added:
    06/28/2024
    Date updated:
    06/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Glaxo Smith Kline
    Topic:
    Honoraria for advisory panel attendance
    Date added:
    06/28/2024
    Date updated:
    06/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Travel
    Ineligible company:
    Glaxo Smith Kline
    Topic:
    Travel to advisory board meeting
    Date added:
    06/28/2024
    Date updated:
    06/28/2024
Return to Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology